HealthKick Podcast: PTX partners with the US’s largest cancer centre on personalised treatment
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class,...
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The...
Prescient Therapeutics (PTX) has partnered with the largest cancer centre in the US to create best-in-class,...
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US...
"We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward...
Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and...
Prescient Therapeutics Ltd (ASX:PTX) managing director and CEO Steven Yatomi-Clarke speaks with Proactive’s Elisha Newell about...
Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.